ALLARITY THERAPEUTICS INC (ALLR) Stock Price & Overview
NASDAQ:ALLR • US0167445008
Current stock price
The current stock price of ALLR is 1.16 USD. Today ALLR is up by 2.65%. In the past month the price increased by 7.62%. In the past year, price increased by 42.84%.
ALLR Key Statistics
- Market Cap
- 18.653M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.31
- Dividend Yield
- N/A
ALLR Stock Performance
ALLR Stock Chart
ALLR Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ALLR. When comparing the yearly performance of all stocks, ALLR is one of the better performing stocks in the market, outperforming 76.11% of all stocks.
ALLR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. ALLR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALLR Earnings
ALLR Forecast & Estimates
7 analysts have analysed ALLR and the average price target is 9.69 USD. This implies a price increase of 735.34% is expected in the next year compared to the current price of 1.16.
ALLR Groups
Sector & Classification
ALLR Financial Highlights
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -2.31. The EPS increased by 94.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.62% | ||
| ROE | -127.47% | ||
| Debt/Equity | 0 |
ALLR Ownership
ALLR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.03 | 380.121B | ||
| AMGN | AMGEN INC | 15.21 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.14 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.63 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.46 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ALLR
Company Profile
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
Company Info
IPO: 2021-12-21
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Phone: 14014264664
ALLARITY THERAPEUTICS INC / ALLR FAQ
Can you describe the business of ALLARITY THERAPEUTICS INC?
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.
What is the stock price of ALLARITY THERAPEUTICS INC today?
The current stock price of ALLR is 1.16 USD. The price increased by 2.65% in the last trading session.
Does ALLARITY THERAPEUTICS INC pay dividends?
ALLR does not pay a dividend.
What is the ChartMill rating of ALLARITY THERAPEUTICS INC stock?
ALLR has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about ALLARITY THERAPEUTICS INC (ALLR) stock?
7 analysts have analysed ALLR and the average price target is 9.69 USD. This implies a price increase of 735.34% is expected in the next year compared to the current price of 1.16.
What is the Short Interest ratio of ALLARITY THERAPEUTICS INC (ALLR) stock?
The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 1.82% of its float.